North Africa Medical Device Registration: Morocco, Algeria & Tunisia Guide (2026)

Why North Africa Matters for Medical Device Manufacturers

North Africa represents one of the fastest-growing medical device markets outside the traditional hubs of the Gulf Cooperation Council. Morocco's medical device market was valued at approximately $236 million in 2025, with imports supplying roughly 85–90% of national demand. Algeria's pharmaceutical and medical device sector is undergoing a top-to-bottom modernization, with the National Agency for Pharmaceutical Products (ANPP) introducing serialization mandates effective January 2027. Tunisia is transitioning to mandatory eCTD submissions by June 2026 under its National Agency of Medicines and Health Products (ANMPS).

Together, these three countries represent a market of over 120 million people with healthcare systems undergoing significant investment and modernization. For medical device manufacturers, understanding the distinct regulatory pathways in each country is essential for successful market entry and sustained commercial operations.

This guide covers the complete registration process in each country, including regulatory authorities, classification systems, documentation requirements, fees, timelines, and the latest 2026 regulatory developments.

Morocco: From DMP to AMMPS — A Regulatory Transformation

Regulatory Authority: AMMPS (formerly DMP)

Morocco's medical device regulatory landscape is undergoing a fundamental transformation. The Directorate of Medicines and Pharmacy (Direction du Médicament et de la Pharmacie, DMP), which traditionally operated under the Ministry of Health, has transitioned into the Moroccan Agency for Medicines and Health Products (AMMPS). As of 2026, AMMPS is fully operational as an autonomous agency with enhanced powers over:

• Product registration and marketing authorization for medical devices and IVDs
• Quality control and laboratory testing
• Pharmacovigilance and post-market surveillance
• Import and export licensing
• Clinical trial oversight
• Enforcement and compliance inspections

The first Board of Directors meeting of AMMPS was presided over by the Prime Minister in March 2025, signaling the highest-level government commitment to this regulatory modernization.

Classification System

Morocco classifies medical devices using an EU MDR-aligned system:

IVD products currently do not have a formal classification system in Morocco, though local technical evaluation may be required for IVD registration.

Registration Requirements

Foreign manufacturers must appoint a Local Authorized Representative based in Morocco. This representative is responsible for:

• Submitting registration applications to AMMPS
• Maintaining compliance with Moroccan regulations from registration through post-market surveillance
• Managing import permits and customs clearance
• Handling variation declarations and vigilance reporting

The required documentation for registration includes:

1. Authorization letter permitting the local company to register and market products
2. CE Certificate or FDA Certificate or Free Sale Certificate (FSC) from country of origin
3. ISO 13485 certificate or equivalent quality management system certification
4. EC Declaration of Conformity for devices and components
5. Labels and nameplate photos (signed and stamped)
6. User manuals (IFUs)
7. Technical file: Product data, maintenance manual, technical specifications, qualifications, test reports, flow charts, manufacturing process descriptions
8. Product catalog (PDF, color)

Fees and Timelines

A registration certificate can only be issued if the proposed device has been the subject of a clinical investigation, a clinical evaluation based on literature, or demonstration of equivalence to devices already on the market. On-site clinical investigations may be required for IVDs.

Language and Labeling Requirements

• Professional-use devices: Documentation, labeling, and IFUs may be provided in English and/or French and/or Arabic
• Consumer/non-professional use devices: Documentation must be in French and/or Arabic
• All labels must include: manufacturer and local representative details, product name and classification, country of origin, lot/serial number, storage conditions, and usage information

The 2026–2030 Local Manufacturing Pact

On February 4, 2026, Morocco signed a landmark framework agreement to develop its domestic medical device industry. The agreement, signed during the second "Medical Device Day" organized by the Moroccan Federation of Health Industries (FMIS) in Casablanca, brings together:

• The Ministry of Health and Social Protection
• The Ministry of Industry and Trade
• The Director General of AMMPS
• The General Confederation of Moroccan Enterprises (CGEM)
• The President of FMIS

Key commitments under this 2026–2030 agreement include:

• Import substitution: Reducing the current 85–90% import dependence for medical devices
• Industrial investment support: Leveraging available investment and export support programs for companies manufacturing locally
• International partnerships: Promoting industrial partnerships between Moroccan and international companies
• Workforce development: Reinforcing training programs to meet sector skills needs
• Made in Morocco branding: Stimulating productive investment and the national brand

The medical device sector currently employs approximately 1,400 people, with investments of MAD 376 million and annual sales approaching MAD 900 million. Nearly half of that value is created locally. The longer-term ambition is to position Morocco as a regional base for exports to the broader African market.

Algeria: ANPP Modernization and the 2027 Serialization Mandate

Regulatory Authority: ANPP

The National Agency for Pharmaceutical Products (Agence Nationale des Produits Pharmaceutiques, ANPP) is the primary regulatory authority for pharmaceuticals and medical devices in Algeria. Created on July 2, 2018, as a financially independent institution under the Ministry of Health, ANPP is gradually replacing the General Directorate of Pharmacy and Health Equipment (DGPES) for regulatory oversight of medical products.

In parallel, the Ministry of the Pharmaceutical Industry (a separate ministry unique to Algeria) also plays a role, particularly regarding establishment licensing and import authorization for pharmaceutical products and medical devices.

Medical Device Registration Framework

Algeria's medical device registration process requires:

1. Application submission to ANPP/MSPRH with complete dossier
2. Preliminary examination resulting in an application receipt
3. Evaluation including laboratory quality control tests where applicable
4. Approval or denial based on quality, safety, and efficacy criteria
5. Granting of market authorization and list price attestation

Foreign manufacturers must work through a local authorized representative or importer who holds the necessary establishment licenses.

The 2027 Serialization and Traceability Mandate

Algeria's most significant regulatory development is the full pharmaceutical serialization and aggregation mandate taking effect January 1, 2027. While initially focused on pharmaceutical products, this framework has implications for medical device manufacturers, particularly those producing combination products or devices in pharmaceutical dosage forms.

Key requirements of the mandate:

• GS1-compliant 2D DataMatrix codes on every unit carton
• Mandatory aggregation for cases and pallets (parent–child packaging data links)
• Four critical data elements: GTIN, randomized unique serial number, batch/lot number, and expiration date
• End-to-end traceability from manufacturer to patient
• EPCIS 1.2/2.0 event reporting capability for supply chain partners

The regulation applies to both locally manufactured and imported products and is coordinated between ANPP, the Ministry of Health, and GS1 Algeria.

New Licensing Requirements for Import Establishments

Ministerial Decree No. 24 of October 1, 2025, establishes comprehensive requirements for licensing pharmaceutical import establishments, including those handling medical devices:

• Authorization validity: 2 years, subject to renewal following inspection
• Compliance deadline: Existing licensed establishments must align with new provisions by September 30, 2026
• Comprehensive application file including: corporate documents, architectural plans at 1/100 scale, organizational chart, recruitment forecast plan, list of products intended for importation
• Compliance charter signed by the Technical Pharmacist Director and General Manager confirming adherence to Good Distribution and Storage Practices
• Inspection by ANPP before authorization is granted

Market Context

Algeria's pharmaceutical and medical device market is substantial, driven by a population of over 45 million and significant government healthcare spending. ANPP publishes regular updates on new product registrations, with a strong focus on promoting local manufacturing of generics and essential medicines. In January–February 2026, ANPP approved 3 new products (2 locally manufactured, 1 imported), reflecting the continued emphasis on domestic production capacity.

Tunisia: eCTD Transition and Regulatory Modernization

Regulatory Authority: DPM / ANMPS

In Tunisia, the Directorate of Pharmacy and Pharmaceuticals (Direction de la Pharmacie et du Médicament, DPM) under the Ministry of Health has traditionally been responsible for medical device registration. The country is transitioning to the National Agency of Medicines and Health Products (ANMPS/ANAM) as the primary regulatory authority.

Registration with DPM is mandatory for the importation and commercial marketing of medical devices and IVDs. Products without DPM registration cannot be cleared through Tunisian customs, stored, or placed on the market.

Classification System

Tunisia does not have a formal medical device classification system comparable to EU MDR or IMDRF frameworks. Instead, all imported products are classified by the Department of Commerce for technical inspection into categories A, B, and C. The regulatory framework is largely aligned with and references:

• EU MDR (2017/745)
• EU IVDR (2017/746)
• IMDRF principles

Registration Requirements

Foreign manufacturers must appoint a Local Authorized Representative in Tunisia who submits applications to the DPM on their behalf. Required documentation includes:

1. Application forms with product details
2. Authorization letter for the local representative
3. CE certificates or Free Sale Certificates
4. ISO 13485 certificate or equivalent
5. Technical documentation
6. Labels and IFUs
7. Product samples (when required)

Timelines and Validity

The eCTD Mandate (2026)

Tunisia's ANMPS is implementing a major modernization of its regulatory submission processes. The updated roadmap, published March 31, 2026, mandates electronic submissions:

• Until May 1, 2026: Submissions continue under the current appointment-based process; major variations remain suspended except those impacting safety or product availability
• From May 1, 2026: Electronic submissions (eCTD or e-submission) become mandatory via three channels: ANMPS eCTD portal, secure file transfer platform, or physical USB drive delivery by appointment
• From June 1, 2026: All submissions must be exclusively in eCTD format
• By June 30, 2026: All dossiers submitted since January 1, 2025 that have not yet been evaluated must be resubmitted in eCTD format

This transition represents a significant modernization step, aligning Tunisia with international best practices in regulatory submissions.

Language and Labeling

• Labels and IFUs must be in French
• Arabic labeling may be required for certain product categories
• Labels must include: manufacturer and local representative details, product name and classification, country of origin, lot/serial number, storage conditions, and usage information

Comparative Summary: North Africa at a Glance

Strategic Considerations for Market Entry

Choosing Your Entry Sequence

For manufacturers considering North African market entry, several strategic factors should guide prioritization:

Morocco offers the most straightforward and predictable registration pathway, with clear timelines (120 days official, 90 days typical), low fees (USD 111), and 5-year validity. The EU-aligned classification system means that manufacturers with CE marking documentation will find the submission requirements familiar. The 2026–2030 local manufacturing pact also signals growing market opportunity.

Tunisia provides a relatively fast approval process (30 days typical for straightforward applications) but requires careful attention to the eCTD transition taking effect in June 2026. Manufacturers should prepare electronic submissions well in advance.

Algeria requires the most patience and adaptation. The regulatory framework is evolving rapidly, with new serialization requirements, establishment licensing rules, and a strong government push toward local manufacturing. The market is large but requires significant local partnership commitment.

Documentation Preparation Across All Three Markets

Common documentation requirements across Morocco, Algeria, and Tunisia include:

• CE certificates or Free Sale Certificates from country of origin
• ISO 13485 quality management system certification
• Technical files with product specifications and test reports
• Authorization letters for local representatives
• Labels and instructions for use
• Clinical evidence or equivalence data

Manufacturers should prepare a core dossier aligned with EU MDR requirements, then adapt for country-specific additions (language translations, local forms, additional certifications).

Post-Market Obligations

All three countries require ongoing post-market compliance:

• Morocco: Variation declarations, device vigilance reporting, and maintenance obligations through the authorized representative
• Algeria: Compliance with Good Distribution and Storage Practices, ANPP inspection requirements, and the forthcoming serialization reporting ecosystem
• Tunisia: Renewal applications at least 6 months before expiry for pharmaceutical products, post-authorization variation submissions, and importation management through the local representative

Key Takeaways

1. Morocco's AMMPS transition in 2026 brings a more structured, digitalized regulatory environment with clear 120-day timelines and USD 111 registration fees — making it the most accessible North African market for new entrants.

2. Algeria's 2027 serialization mandate (GS1 2D DataMatrix, mandatory aggregation) represents the most significant regulatory compliance challenge in the region. Manufacturers should begin preparation now, including line upgrades for 2D printing and vision verification.

3. Tunisia's eCTD mandate from June 2026 requires all regulatory submissions to be in electronic Common Technical Document format. Companies should prepare electronic dossiers and establish ANMPS portal access well before the deadline.

4. The 2026–2030 Morocco manufacturing pact signals a regional shift toward local production. Manufacturers should consider whether local manufacturing partnerships or technology transfer arrangements could provide competitive advantages.

5. All three countries require local representatives — the choice of representative is critical, as they hold the registration certificate and manage all regulatory interactions. Selecting an independent professional representative, rather than a commercial distributor, protects regulatory assets and provides flexibility.